- Home
- ZNTL vs NEWT Comparison
ZNTL vs NEWT Comparison
Compare ZNTL & NEWT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ZNTL | NEWT |
|---|---|---|
| Founded | 2014 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 156.7M | 395.5M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | ZNTL | NEWT |
|---|---|---|
| Price | $2.10 | $10.46 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 2 |
| Target Price | $6.60 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 543.2K | 183.9K |
| Earning Date | 03-26-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 6.87% |
| EPS Growth | ★ 18.03 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.45 |
| P/E Ratio | ★ N/A | $5.99 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.01 | $9.12 |
| 52 Week High | $3.95 | $14.91 |
Technical Indicators
Market Signals| Indicator | ZNTL | NEWT |
|---|---|---|
| Relative Strength Index (RSI) | 38.84 | 26.39 |
| Support Level | $2.10 | $10.28 |
| Resistance Level | $2.69 | $12.41 |
| Average True Range (ATR) | 0.23 | 0.37 |
| MACD | -0.04 | -0.09 |
| Stochastic Oscillator | 0.42 | 0.50 |
Price Performance
Historical ComparisonAbout ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
About NEWT NewtekOne Inc.
NewtekOne Inc is a financial holding company engaged in providing financial solutions to its Client Base. It is an internally managed non-diversified closed-end management investment company. It has four reportable segments Banking, Alternative Lending, Technology, NSBF, and Payments.